Company Profile
Genmab Stock Price, News & Analysis
- Ticker:
- GMAB
- Exchange:
- NASDAQ
- Sector:
- Antibody Drugs
- Location:
- Copenhagen, Denmark
Stock performance
29.83 USD (+1.95%)
Close
Last updated: August 6, 2026
14.6B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, GMAB closed up 1.95% at $29.83. No new same-company headline was identified in the current news window.
Company overview
Business overview
Genmab is an antibody-focused biotechnology company with a long record of discovering and advancing differentiated cancer therapeutics. The company is known for its antibody engine, its partnered programs, and its ability to turn discovery into commercial or royalty-based value.
Geographic Base and Sector Classification
Headquartered in Copenhagen, Denmark and listed on Nasdaq Copenhagen and as an ADR in the U.S., Genmab is a global biotechnology company. Its footprint spans Europe and the United States.
Business Model Characteristics
Genmab combines internal R&D with partnered programs, milestone revenue, and royalty income from successful antibodies. Investors follow clinical data, partner progress, and whether the company can keep producing validated antibodies from its discovery platform.
Position Within the Biotechnology Landscape
Genmab sits in the premium end of antibody biotech because it has both scientific credibility and economic leverage from partnerships. The stock can move on data, deal flow, or royalty updates, making it a platform-driven catalyst name.
Future catalysts
Genmab’s next three months are likely to focus on epcoritamab, combination data, and any label or expansion steps that deepen the antibody franchise. That readout matters because it decides whether the asset is ready for a larger and more expensive development step. If the data come in cleanly, the market tends to give the broader platform behind the program more credit.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Genmab (GMAB)?
Genmab (GMAB) most recently closed at 29.83 USD, a +1.95% move versus the previous session.
What is the market cap of Genmab (GMAB)?
Genmab currently has a market capitalization of 14.6B USD on BioPharmSignal.
What does Genmab do?
Genmab is an antibody-focused biotechnology company with a long record of discovering and advancing differentiated cancer therapeutics. The company is known for its antibody engine, its partnered programs, and its ability to turn discovery into commercial or royalty-based value.
On which exchange is GMAB stock listed?
Genmab (GMAB) is associated with NASDAQ, Copenhagen, Denmark, Antibody Drugs.
What is epcoritamab?
Genmab’s next three months are likely to focus on epcoritamab, combination data, and any label or expansion steps that deepen the antibody franchise.
Which conditions is Genmab targeting with epcoritamab?
Genmab is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Genmab describe recent progress with epcoritamab?
Genmab’s next three months are likely to focus on epcoritamab, combination data, and any label or expansion steps that deepen the antibody franchise.
What is Genmab?
Genmab is an antibody-focused biotechnology company with a long record of discovering and advancing differentiated cancer therapeutics.